Literature DB >> 18007679

Specificity of T-cell alloreactivity.

Nathan J Felix1, Paul M Allen.   

Abstract

T-cell alloreactivity is a well-established phenomenon, but its molecular basis has remained enigmatic. Although there are differences between T-cell recognition of conventional and allogeneic antigens, it has become increasingly clear that they share many similarities. Recent insights into the specificity of the T-cell receptor (TCR) for peptide and the seeming intrinsic affinity of the TCR for the surface of the MHC molecule have provided a better understanding of how the TCR and peptide-MHC complexes interact. Here, we highlight the similarities and differences between conventional and allogeneic recognition of TCR-peptide-MHC complexes, and discuss how our view of allorecognitionhas changed, as well as the implications for TCR specificity and T-cell development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18007679     DOI: 10.1038/nri2200

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  99 in total

1.  Reconciling views on T cell receptor germline bias for MHC.

Authors:  K Christopher Garcia
Journal:  Trends Immunol       Date:  2012-07-06       Impact factor: 16.687

Review 2.  Acute rejection.

Authors:  Mark Benzimra; Greg L Calligaro; Allan R Glanville
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

3.  An automated algorithm for extracting functional immunologic V-genes from genomes in jawed vertebrates.

Authors:  David Olivieri; Jose Faro; Bernardo von Haeften; Christian Sánchez-Espinel; Francisco Gambón-Deza
Journal:  Immunogenetics       Date:  2013-06-22       Impact factor: 2.846

4.  Generation of human alloantigen-specific T cells from peripheral blood.

Authors:  Burhan P Jama; Gerald P Morris
Journal:  J Vis Exp       Date:  2014-11-21       Impact factor: 1.355

5.  Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research.

Authors:  Aleksandr Lazaryan; Tao Wang; Stephen R Spellman; Hai-Lin Wang; Joseph Pidala; Taiga Nishihori; Medhat Askar; Richard Olsson; Machteld Oudshoorn; Hisham Abdel-Azim; Agnes Yong; Manish Gandhi; Christopher Dandoy; Bipin Savani; Gregory Hale; Kristin Page; Menachem Bitan; Ran Reshef; William Drobyski; Steven Ge Marsh; Kirk Schultz; Carlheinz R Müller; Marcelo A Fernandez-Viña; Michael R Verneris; Mary M Horowitz; Mukta Arora; Daniel J Weisdorf; Stephanie J Lee
Journal:  Haematologica       Date:  2016-05-31       Impact factor: 9.941

6.  Tolerance induction using nanoparticles bearing HY peptides in bone marrow transplantation.

Authors:  Kelan A Hlavaty; Derrick P McCarthy; Eiji Saito; Woon Teck Yap; Stephen D Miller; Lonnie D Shea
Journal:  Biomaterials       Date:  2015-10-21       Impact factor: 12.479

7.  Defective in vitro IL-2 production in lupus is an early but secondary event paralleling disease activity: evidence from the murine parent-into-F1 model supports staging of IL-2 defects in human lupus.

Authors:  Charles S Via; Gene M Shearer
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

8.  Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.

Authors:  Marvin M van Luijn; Martine E D Chamuleau; James A Thompson; Suzanne Ostrand-Rosenberg; Theresia M Westers; Yuri Souwer; Gert J Ossenkoppele; S Marieke van Ham; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

9.  Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA.

Authors:  Nadia Mensali; Fan Ying; Vincent Oei Yi Sheng; Weiwen Yang; Even Walseng; Shraddha Kumari; Lars-Egil Fallang; Arne Kolstad; Wolfgang Uckert; Karl Johan Malmberg; Sébastien Wälchli; Johanna Olweus
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

10.  DC expressing transgene Foxp3 are regulatory APC.

Authors:  Michael W Lipscomb; Jennifer L Taylor; Cristina J Goldbach; Simon C Watkins; Amy K Wesa; Walter J Storkus
Journal:  Eur J Immunol       Date:  2010-02       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.